Filing Details
- Accession Number:
- 0001649094-24-000071
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-19 17:48:24
- Reporting Period:
- 2024-09-18
- Accepted Time:
- 2024-09-19 17:48:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649094 | Vaxcyte Inc. | PCVX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1230724 | Andrew Guggenhime | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | President And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-18 | 8,000 | $5.35 | 98,383 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-18 | 5,485 | $115.60 | 92,898 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-18 | 1,686 | $116.29 | 91,212 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-09-18 | 829 | $117.53 | 90,383 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-09-18 | 8,000 | $0.00 | 8,000 | $5.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 320,827 | 2030-05-11 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $115.06 to $115.95. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $116.06 to $116.75. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $117.11 to $117.89. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
